EWTX

Edgewise Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website edgewisetx.com
Employees(FY) 80
ISIN US28036F1057

Performance

-9.23%

-10.18%

+69.77%

+76.42%

+192.05%

YTD

+396.89%

Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Advanced Technical Analysis

Technical Analysis of EWTX 2024-11-20

The stock's indicators reflect a neutral sentiment, with the Moving Average Score at 50 indicating a balanced trend, while the Oscillators and Technical Scores at 46 and 48 suggest a slight bearish inclination. Overall, the combined scores imply a cautious market outlook, warranting careful observation before making investment decisions.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of EWTX

Stock Rank

Recent News & Updates

2024-11-08 09:57
RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating(MT Newswires)
2024-11-07 08:00
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights(Business Wire)
2024-11-06 19:00
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights(Businesswire)
2024-10-07 17:37
Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now(Insider Monkey)
2024-10-01 08:00
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society(Business Wire)
2024-09-30 20:00
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society(Businesswire)
2024-09-20 07:28
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data(BioPharma Dive)
2024-09-20 06:26
RBC Raises Price Target on Edgewise Therapeutics to $42 From $32, Keeps Outperform, Speculative Risk(MT Newswires)
2024-09-20 05:05
Company News for Sep 20, 2024(Zacks)
2024-09-20 04:52
Edgewise’s EDG-7500 shows benefit in two obstructive HCM trials(Clinical Trials Arena)
2024-09-19 16:08
How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease(Investor's Business Daily)
2024-09-19 14:51
Leerink Partners Raises Edgewise Therapeutics' Price Target to $42 From $32, Outperform Rating Maintained(MT Newswires)
2024-09-19 13:51
Top Midday Gainers(MT Newswires)
2024-09-19 12:55
Why Edgewise Therapeutics Stock Is Up 50% on Thursday(Motley Fool)
2024-09-19 12:31
Wedbush Adjusts Edgewise Therapeutics Price Target to $44 From $31, Maintains Outperform Rating(MT Newswires)
2024-09-19 09:22
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip(Investor's Business Daily)
2024-09-19 09:19
Sector Update: Health Care Stocks Rise Premarket Thursday(MT Newswires)
2024-09-19 07:00
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)(Business Wire)
2024-09-18 19:00
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)(Businesswire)
2024-09-17 16:01
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time(Business Wire)
2024-09-17 04:01
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time(Businesswire)
2024-08-10 09:49
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation(Simply Wall St.)
2024-08-08 08:00
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights(Business Wire)
2024-08-07 20:00
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights(Businesswire)
2024-07-30 12:25
7 Small-Cap Stocks to Buy for Large-Scale Gains(InvestorPlace)
2024-07-21 09:00
‘Don’t Be Scared of Heights’: J.P. Morgan Suggests 2 Stocks to Buy(TipRanks)
2024-07-17 12:00
Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy(Zacks)
2024-07-16 16:02
Three Surprising Names That Could Be On Biogen's Buyout Shortlist(Investor's Business Daily)
2024-07-16 11:55
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense(Investor's Business Daily)
2024-07-09 14:17
Top Midday Gainers(MT Newswires)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.